

Antihypertensive effects of *m*-nisoldipine and nisoldipine on conscious renal hypertensive rats and dogs

LIU Wen-Hu, FU Shao-Xuan, LI Yun-Shan

(Department of Pharmacology, Hebei Medical College, Shijiazhuang 050017, China)

ABSTRACT The antihypertensive effects of *m*-nisoldipine (*m*-Nis) and nisoldipine (Nis) by ig 0.3, 1.0, 3.0 and 1.0, 3.0, 9.0 mg · kg⁻¹ respectively on renal hypertensive rats (RHR) and 0.1, 0.3, 1.0 mg · kg⁻¹ orally (for both drugs) on renal hypertensive dogs (RHD) were studied. Both *m*-Nis and Nis depressed blood pressure (BP) dose-dependently in RHR and RHD. The reduction of blood pressure correlated well with the *m*-Nis concentration in plasma of RHD. On the basis of ED₂₀ (HR)/ED₂₀ (BP), the hypotensive effect of *m*-Nis on systolic blood pressure (SBP) was only 1.6 times as great as that of Nis on RHR (*P* < 0.05), but in RHD, both drugs showed the same potency (*P* > 0.05). In both models, *m*-Nis showed much more potent effect on diastolic blood pressure (DBP) than Nis (*P* < 0.01), and possessed stronger hypotensive effects on DBP than on SBP (*P* < 0.05 and *P* < 0.01); but for Nis, its effects on SBP and DBP appeared to be in the same order (*P* > 0.05). The fall in BP was accompanied by a transient increase of heart rates (HR) with *m*-Nis and Nis in RHR and RHD. The chronic antihypertensive effects of *m*-Nis and Nis were also remarkable with 1.0 mg · kg⁻¹ daily at 9 AM for 21 d. During this period, the BP and HR lowered to nearly normal level. After withdrawal of *m*-Nis and Nis, the hypotensive effects lasted nearly 1 wk.

KEY WORDS antihypertensive agents; renovascular hypertension; dogs; rats; *m*-nisoldipine; nisoldipine

Nisoldipine (Nis) possessed vascular selectivity and exhibited a long-lasting hypotensive effects on renal hypertensive dogs (RHD)^(1,2). *m*-Nis was first developed in the Department of Organic Chemistry, Hebei Medical College, and our previous papers

reported that *m*-Nis shared the same characteristics as Nis and was much more stable to sunlight and heat compared with Nis⁽³⁻⁸⁾.

The present study was undertaken to evaluate the effectiveness of *m*-Nis in RHR and RHD and its plasma concentrations.

MATERIALS AND METHODS

Renal hypertensive rats The ♂ Sprague-Dawley rats, weighing 150 ± s 16 g were used to prepare RHR (1K1C) by clipping the renal artery⁽⁹⁾. After operation, rats received a standard diet and saline. After 8 wk, body weight increased to 315 ± 14 g and BP reached 22.7 / 18.0-25.3 / 21.3 kPa were used in the experiments. Groups of 8 RHR were used to test the hypotensive effects of *m*-Nis and Nis (supported by the Department of Pharmacy of our College). *m*-Nis and Nis were protected from light in all the procedures. The drugs were suspended in 0.5% carboxymethylcellulose (CMC) and giving at a volume of 3 ml · kg⁻¹ by stomach tube. SBP, DBP, and HR were monitored before and 0.5, 1, 2, 3, 4, 6, 8, 12, 24 h after ig by tail cuff method⁽⁹⁾. RHR were allowed to take saline *ad lib* but no food for 24 h in the laboratory at 30°C before the experiments.

Renal hypertensive dogs Dogs, both sexes, weighing 15 ± 4 kg were prepared (2K1C) by renal artery constriction⁽¹⁰⁾. At the same time, a left carotid artery loop was made. After operation, the dogs were injected im penicillin 800 000 u at 9 AM and 5 PM daily, and kept in the laboratory with room temperature of 20°C for 10 d. RHD with BP above 21.3 / 17.3 kPa were employed

Received 1990 Nov 15

Accepted 1991 Sep 4

in the experiments. SBP, DBP, and HR were measured on the carotid artery loop with a stethoscope.

m-Nis and Nis were freshly suspended in 0.5% CMC ($0.1 \text{ mg} \cdot \text{kg}^{-1}$ group) or weighed accurately (0.3 and $1.0 \text{ mg} \cdot \text{kg}^{-1}$ groups) just before the test. The drugs in the meat soup were given orally according to a cross-over design. The washout period of a drug was 5 d before the subsequent experiment. *m*-Nis and Nis were protected from light also. In the chronic test, the RHD were given *m*-Nis or Nis $1.0 \text{ mg} \cdot \text{kg}^{-1}$ at 9 AM daily for 21 d.

The plasma concentration of *m*-Nis was measured in RHD with 0.3 and $1.0 \text{ mg} \cdot \text{kg}^{-1}$ single doses with HPLC⁽¹¹⁻¹³⁾.

Statistical analysis Values were expressed as the $\bar{x} \pm s$. Comparison between values before and after medication was carried out with paired *t* test. Correlation coefficient was calculated by linear regression analysis. The doses required to decrease BP or increase HR by 20% of the initial values (ED_{20}) were measured⁽¹⁴⁾.

RESULTS

Antihypertensive effects of *m*-Nis and Nis on RHR The reductions of SBP and DBP were seen after 30 min and reached the peak effects at 1 h after medication. The maximal depressive duration of *m*-Nis and Nis were about 8 and 6 h (on SBP), 8 and 12 h (on DBP) respectively. At 1 and $3 \text{ mg} \cdot \text{kg}^{-1}$ (*m*-Nis) or 3 and $9 \text{ mg} \cdot \text{kg}^{-1}$ (Nis), transient increases of HR were seen from 30 min to 3 h after dosing (Fig 1).

Antihypertensive effects of *m*-Nis and Nis on RHD The hypotensive effects started from 30 min and the maximal effects attained at 1 h after medication. The maximal hypotensive duration of *m*-Nis or Nis lasted 6 and 6 h (on SBP) or 8 and 6 h (on DBP) respectively with the largest dose. There was




Fig 1. Effects of single ig dose of *m*-nisoldipine or nisoldipine in conscious renal hypertensive rats. $n=8$, \circ control (CMC), \bullet 0.3 , \times 1.0 , \square $3.0 \text{ mg} \cdot \text{kg}^{-1}$ for *m*-Nis in 0.5% CMC solution; \bullet 1.0 , \times 3.0 , \square $9.0 \text{ mg} \cdot \text{kg}^{-1}$ for Nis in 0.5% CMC. $\bar{x} \pm s$, $**P < 0.05$, $***P < 0.01$ vs before.

also a transient positive chronotropic effect at 1–8 h, but the peak effects occurred at about 3 h after oral dosing (Fig 2).

Plasma concentration of *m*-Nis in RHD The plasma concentrations of *m*-Nis with single doses of 0.3 or $1.0 \text{ mg} \cdot \text{kg}^{-1}$ correlated well with the reduction of BP ($r=0.9987$) (Fig 3).

Chronic antihypertensive effects of *m*-Nis and Nis on RHD During the 21 d treatment with both drugs, there were no positive chronotropic effects, but the BP were reduced from d 3 and persisted in a lower and stable state. After withdrawal of both drugs, the hypotensive effects lasted nearly 1 wk (Fig 4).

DISCUSSION

In RHR, the ED_{20} value of Nis for




Fig 2. Effects of single oral dose of *m*-Nis or Nis on conscious renal hypertensive dogs. $n=6$, \circ 0.1, \bullet 0.3, \times 1.0 $\text{mg} \cdot \text{kg}^{-1}$ for both drugs. $\bar{x} \pm s$, $**P < 0.05$, $***P < 0.01$ vs before.




Fig 3. Plasma concentrations of *m*-Nis vs reductions of systolic (\circ) and diastolic (\bullet) blood pressures from 6 renal hypertensive dogs with single oral dose of 0.3 or 1.0 $\text{mg} \cdot \text{kg}^{-1}$. $\bar{x} \pm s$.

HR, SBP or DBP was 1 to 5 times greater than that of *m*-Nis, which suggested that *m*-Nis was more potent on these three parameters. But in RHD, the ED_{20} value of




Fig 4. Effects of *m*-Nis and Nis, both 1.0 $\text{mg} \cdot \text{kg}^{-1} \cdot \text{d}^{-1} \times 21 \text{ d}$ on renal hypertensive dogs. $\bar{x} \pm s$, $**P < 0.05$, $***P < 0.01$ vs before.

m-Nis on HR or SBP was almost equal to what of Nis respectively. Only the ED_{20} value of Nis on DBP was 2 times as great as what of *m*-Nis, which disagreed with our previous results in anesthetized normotensive dogs⁽³⁾. These differences may be due to the species and the conditions of animals. So according to the ED_{20} values, it is suggested that *m*-Nis could reduce the DBP predominantly compared with Nis in conscious RHD (Tab 1).

On the basis of $\text{ED}_{20}(\text{HR})/\text{ED}_{20}(\text{BP})$, our results demonstrated that *m*-Nis reduced the SBP a little greater than Nis in RHR, but in RHD, both drugs showed the same potent hypotensive effect on SBP; the potency of *m*-Nis to reduce DBP was 1 time higher than Nis in both models, and the reduction of DBP induced by *m*-Nis was 0.5 to 1 time greater than that of SBP. During the chronic treatment with both drugs, the blood pressure was reduced down to nearly normal levels. And from d 3 to the end of treatment, the blood pressure persisted in a lower and stable state. Along with the

Tab 1. ED₂₀ of *m*-nisoldipine or nisoldipine on renal hypertensive dogs (RHD) and rats (RHR). ED₂₀ = the dose to reduce BP or increase HR by 20%.

	<i>m</i> -Nis	Nis
ED ₂₀ / mg · kg ⁻¹		
RHR (n=24, ig)		
HR	3.45	7.85
SBP	0.87	3.19
DBP	0.60	3.08
RHD (n=18, po)		
HR	2.13	2.00
SBP	0.54	0.49
DBP	0.27	0.56
ED ₂₀ (HR) / ED ₂₀ (SBP)		
RHR	3.96	2.46
RHD	3.94	4.08
ED ₂₀ (HR) / ED ₂₀ (DBP)		
RHR	5.75	2.55
RHD	7.89	3.57

reduction of blood pressure, there were no increase of HR but a negative chronotropic effects disclosed.

As a result, our experiments demonstrated that *m*-Nis possessed potent antihypertensive effects on RHR and RHD, especially reduced DBP predominantly in both hypertensive models compared with Nis.

ACKNOWLEDGMENTS WU Zhan-Jun, WANG Yong-Li, ZHAO Yun-Kun, and WANG Lan-Fen for their assistance in the preparation of RHD and JIANG Qiu-Fen, WANG Yong-Li, and HUANG Yuan for their excellent technical assistance in HPLC.

REFERENCES

- Kazda S, Garthoff B, Meyer H, Schloßmann K, Stoepel K, Towart R, *et al*. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate (nisoldipine, Bay k 5552). *Arzneimittelforschung* 1980; 30(II) : 2144-62.
- Friedel HA, Sorkin EM. Nisoldipine, a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. *Drugs* 1988; 36 : 682.
- Fu SX, Li YS, Jin CJ, Ren LM. Effects of *m*-nisoldipine and nisoldipine on hemodynamics in anesthetized dogs. *Acta Pharmacol Sin* 1988; 9 : 43-8.
- Ren LM, Li YS, Fu SX, Jin CJ. Cardiovascular action of *m*-nisoldipine in anaesthetized rabbits and guinea pigs. *Acta Pharmacol Sin* 1988; 9 : 426-30.
- Li YL, Fu SX, Li YS. Prophylactic effects of *m*-nisoldipine and nisoldipine on reperfusion arrhythmia in hearts of rats. *Acta Pharmacol Sin* 1988; 9 : 542-7.
- Zhang HL, Fu SX, Li YS. Protective effects of *m*-nisoldipine and nisoldipine on myocardial damage in working rabbit hearts after ischemia-reperfusion. *Acta Pharmacol Sin* 1989; 10 : 49-53.
- An RH, Fu SX, Li YS. Effects of *m*-nisoldipine on ischemic arrhythmia in conscious rats. *Acta Pharmacol Sin* 1989; 10 : 151-6.
- Gao YJ, Li YS, Fu SX. Effects of *m*-nisoldipine on rabbit cardiac and vascular preparations *in vitro*: a comparison with nisoldipine. *Chin J Pharmacol Toxicol* 1990; 4 : 21-5.
- Tasaka K, Kamei C, Tagami H, Hokonohara T, Sugimoto Y. Antihypertensive effects of nisoldipine and reference drugs in certain types of hypertensive rats. *Arzneimittelforschung* 1987; 37(I) : 316-21.
- Takata Y, Kato H. Comparative study on acute antihypertensive effects and pharmacokinetics of nisoldipine, nifedipine, nimodipine and nicardipine administered orally to conscious renal hypertensive dogs. *Arzneimittelforschung* 1986; 36(II) : 1464-71.
- Huang Y, Fu SX, Li YS. Pharmacokinetics of *m*-nisoldipine in rabbits and rats. *Acta Pharmacol Sin* 1990; 11 : 484-7.
- Wu AT, Massey IJ, Kushinsky S. A high-performance liquid chromatographic method for the simultaneous determination of nicardipine and its pyridine metabolite II in plasma. *J Pharm Sci* 1984; 73 : 1444-7.
- Kleinbloesem CH, van Brummelen P, van de Linde JA, Voogd PJ, Breimer DD. Nifedipine: kinetics and dynamics in healthy subjects. *Clin Pharmacol Ther* 1984; 35 : 742-9.

14 Stoepel K, Heise A, Kazda S. Pharmacological studies of the antihypertensive effect of nitrendipine. *Arzneimittelforschung* 1981; 31 (II): 2056-61.

⑥

31-35

间尼索地平 and 尼索地平对清醒肾性高血压大鼠及犬的抗高血压作用

刘文虎, 傅绍莹, 李蕴山 R969.4
(河北医学院药理教研室, 石家庄 050017, 中国)

摘要 间尼索地平(m-Nis)降低 SBP 在肾性高血压大鼠(RHR, ig)强于尼索地平(Nis, P<0.05); 在肾性高血压犬(RHD, po)相近 (P>0.05), 降压作用与其血药浓度呈正相关. 在 RHR 和 RHD, m-Nis 降低 DBP 强于 Nis (P<0.01), 优于降低 SBP (P<0.05 和 P<0.01), Nis 对 SBP 和 DBP 作用相似(P>0.05). 降压作用均伴有心率加快. 连续灌服 21 天, 明显而平稳地降低 RHD 血压, 停药后仍持续约一周.

关键词 降压剂; 肾血管高血压; 犬; 大鼠; 间尼索地平; 尼索地平

BIBLID: ISSN 0253-9756 中国药理学报 Acta Pharmacologica Sinica 1992 Jan; 13 (1): 35-38

⑦

35-38

钩藤碱和异钩藤碱对麻醉犬血压及器官血流的作用¹

石京山, 刘国雄, 吴芹 (遵义医学院药理教研室, 遵义 563003, 中国) R969.1
黄一平, 张光德 (广西中医药研究所, 南宁 530022, 中国)

Effects of rhynchophylline and isorhynchophylline on blood pressure and blood flow of organs in anesthetized dogs

SHI Jin-Shan, LIU Guo-Xiong, WU Qin
(Department of Pharmacology, Zunyi Medical college, Zunyi 563003, China)
HUANG Yi-Ping, ZHANG Xian-De
(Guangxi Institute of Traditional Chinese Medicine and Materia Medica, Nanning 530022, China)

ABSTRACT In anesthetized thoracotomized dogs, rhynchophylline (Rhy 5 mg · kg⁻¹, iv) reduced the mean arterial pressure (MAP), heart rate (HR), and coronary blood flow (CBF) by 1.16 ± 0.67 kPa, 19 ± 12 beats/min, and 0.12 ± 0.04 ml · min⁻¹ · g⁻¹, whereas isorhynchophylline (Isorhy 1 mg · kg⁻¹, iv) reduced the parameters by 3.58 ± 0.19 kPa, 26 ± 18 beats/min, and 0.10 ± 0.04 ml · min⁻¹ · g⁻¹, respectively. In unthoracotomized

dogs, Rhy (10 mg · kg⁻¹, iv) decreased renal blood flow (RBF) by 0.35 ± 0.16 ml · min⁻¹ · g⁻¹, but did not change the MAP. Isorhy (5 mg · kg⁻¹, iv) reduced the MAP by 3.44 ± 1.44 kPa, but the RBF remained unaffected. These results indicated that the hypotensive effect of Isorhy in a dosage not affecting RBF was more potent than that of Rhy.

KEY WORDS rhynchophylline; isorhynchophylline; blood pressure; blood flow velocity; hemodynamics; oxygen consumption

摘要 Rhy 5 mg · kg⁻¹ iv 使麻醉开胸犬的 MAP, HR 及 CBF 分别下降 1.16 ± 0.67 kPa, 19 ± 12 beats/min 及 0.12 ± 0.04 ml · min⁻¹ · g⁻¹, Isorhy 1 mg · kg⁻¹ iv 使上述指标分别下降 3.58 ± 0.19 kPa, 26 ± 18 beats/min 和 0.10 ± 0.04 ml · min⁻¹ · g⁻¹; 在未开胸犬, Rhy 10 mg · kg⁻¹ iv 对 MAP 无明显影响, 但 RBF 减少 0.35 ± 0.16 ml · min⁻¹ · g⁻¹, Isorhy 5 mg · kg⁻¹ iv 使 MAP 降低 3.44 ± 1.44 kPa 而 RBF 不变. 结果提示 Isorhy 的降压作用强于 Rhy 且对 RBF 无不良影响.

Received 1991 Feb 5 Accepted 1991 Sep 3
¹Project supported by the Natural Science Foundation of Guizhou Province, No893038

关键词 钩藤碱; 异钩藤碱; 血压; 血流速度; 血液动力学; 氧消耗